dihydroxyphenylalanine has been researched along with Acute Confusional Senile Dementia in 14 studies
Dihydroxyphenylalanine: A beta-hydroxylated derivative of phenylalanine. The D-form of dihydroxyphenylalanine has less physiologic activity than the L-form and is commonly used experimentally to determine whether the pharmacological effects of LEVODOPA are stereospecific.
dopa : A hydroxyphenylalanine carrying hydroxy substituents at positions 3 and 4 of the benzene ring.
| Excerpt | Relevance | Reference |
|---|---|---|
| "For example, in substantia nigra in Parkinson's diseases key alterations occur, in iron handling, mitochondrial function and antioxidant defences, particularly reduced glutathione." | 2.39 | Oxidative stress in Parkinson's disease and other neurodegenerative disorders. ( Jenner, P, 1996) |
| "The selective VTA DAergic neuron degeneration results in lower DA outflow in the hippocampus and nucleus accumbens (NAc) shell." | 1.46 | Dopamine neuronal loss contributes to memory and reward dysfunction in a model of Alzheimer's disease. ( Aversa, D; Berretta, N; Cavallucci, V; Coccurello, R; Cordella, A; Cutuli, D; D'Amelio, M; De Bartolo, P; Dell'Acqua, MC; Federici, M; Giacovazzo, G; Keller, F; Krashia, P; Latagliata, EC; Marino, R; Mercuri, NB; Nobili, A; Petrosini, L; Puglisi-Allegra, S; Rizzo, FR; Sancandi, M; Viscomi, MT, 2017) |
| "21 patients who had Parkinson's disease (PD), PD plus dementia of Alzheimer type (PDAT) or progressive supranuclear palsy (PSP), were studied with positron emission tomography (PET) using (18F)-2-fluoro-2-deoxy-D-glucose (FDG)." | 1.28 | Positron emission tomography in degenerative disorders of the dopaminergic system. ( Heiss, WD; Herholz, K; Holthoff, V; Huber, M; Karbe, H; Wagner, R; Wienhard, K, 1992) |
| "Patients with Parkinson's disease have a decrement in homovanillic acid that is reversed by treatment with L-3,4-dihydroxyphenylalanine." | 1.27 | Monoamine metabolites in human cerebrospinal fluid. HPLC/ED method. ( Aguado, EG; de Yebenes, JG; Mena, MA, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (14.29) | 18.7374 |
| 1990's | 7 (50.00) | 18.2507 |
| 2000's | 1 (7.14) | 29.6817 |
| 2010's | 3 (21.43) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Pineda-Pardo, JA | 1 |
| Gasca-Salas, C | 1 |
| Fernández-Rodríguez, B | 1 |
| Rodríguez-Rojas, R | 1 |
| Del Álamo, M | 1 |
| Obeso, I | 1 |
| Hernández-Fernández, F | 1 |
| Trompeta, C | 1 |
| Martínez-Fernández, R | 1 |
| Matarazzo, M | 1 |
| Mata-Marín, D | 1 |
| Guida, P | 1 |
| Duque, A | 1 |
| Albillo, D | 1 |
| Plaza de Las Heras, I | 1 |
| Montero, JI | 1 |
| Foffani, G | 1 |
| Toltsis, G | 1 |
| Rachmilevitch, I | 1 |
| Blesa, J | 1 |
| Obeso, JA | 1 |
| Nobili, A | 1 |
| Latagliata, EC | 1 |
| Viscomi, MT | 1 |
| Cavallucci, V | 1 |
| Cutuli, D | 1 |
| Giacovazzo, G | 1 |
| Krashia, P | 1 |
| Rizzo, FR | 1 |
| Marino, R | 1 |
| Federici, M | 1 |
| De Bartolo, P | 1 |
| Aversa, D | 1 |
| Dell'Acqua, MC | 1 |
| Cordella, A | 1 |
| Sancandi, M | 1 |
| Keller, F | 1 |
| Petrosini, L | 1 |
| Puglisi-Allegra, S | 1 |
| Mercuri, NB | 1 |
| Coccurello, R | 1 |
| Berretta, N | 1 |
| D'Amelio, M | 1 |
| Tsunoda, T | 1 |
| Takase, M | 1 |
| Shigemori, H | 1 |
| Veronese, M | 1 |
| Moro, L | 1 |
| Arcolin, M | 1 |
| Dipasquale, O | 1 |
| Rizzo, G | 1 |
| Expert, P | 1 |
| Khan, W | 1 |
| Fisher, PM | 1 |
| Svarer, C | 1 |
| Bertoldo, A | 1 |
| Howes, O | 1 |
| Turkheimer, FE | 1 |
| Li, J | 1 |
| Zhu, M | 1 |
| Manning-Bog, AB | 1 |
| Di Monte, DA | 1 |
| Fink, AL | 1 |
| Mena, MA | 1 |
| Aguado, EG | 1 |
| de Yebenes, JG | 1 |
| Itoh, M | 2 |
| Meguro, K | 2 |
| Fujiwara, T | 2 |
| Hatazawa, J | 1 |
| Iwata, R | 1 |
| Ishiwata, K | 1 |
| Takahashi, T | 1 |
| Ido, T | 1 |
| Sasaki, H | 1 |
| Jenner, P | 1 |
| Yamaguchi, S | 1 |
| Yamadori, A | 1 |
| Raskind, MA | 1 |
| Peskind, ER | 1 |
| Holmes, C | 1 |
| Goldstein, DS | 2 |
| Karbe, H | 1 |
| Holthoff, V | 1 |
| Huber, M | 1 |
| Herholz, K | 1 |
| Wienhard, K | 1 |
| Wagner, R | 1 |
| Heiss, WD | 1 |
| Barker, R | 1 |
| Liu, HC | 1 |
| Yang, JC | 1 |
| Chang, YF | 1 |
| Liu, TY | 1 |
| Chi, CW | 1 |
| Eisenhofer, G | 1 |
| Stull, R | 1 |
| Keiser, HR | 1 |
| Sunderland, T | 1 |
| Murphy, DL | 1 |
| Kopin, IJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Study to Evaluate the Safety and Feasibility of Temporary Blood Brain Barrier Disruption (BBBD) Using Exablate MR Guided Focused Ultrasound in Patients With Parkinson's Disease Dementia[NCT03608553] | 10 participants (Anticipated) | Interventional | 2018-11-26 | Active, not recruiting | |||
| Prazosin for Disruptive Agitation in Alzheimer's Disease (AD) (PEACE-AD)[NCT03710642] | Phase 2 | 35 participants (Actual) | Interventional | 2018-10-23 | Completed | ||
| Reference Values for Plasma Catechols[NCT00267904] | Phase 1 | 46 participants (Actual) | Interventional | 2006-03-08 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The ADCS-ADL-Severe questionnaire is a secondary outcome measure aimed at detecting functional decline in people with severe AD. This scale is best suited for evaluating people with MMSE scores below 15/30, or equivalent. Questions are administered to a qualified caregiver informant about a set of 19 basic and instrumental ADL. Instrumental ADL are selected to be relevant to this level of severity of dementia, e.g., obtaining a beverage, turning lights on and off, turning a faucet on and off. Performance of each of these activities during the past 4 weeks, as well as the level of performance, are rated. A total score is derived by summing scores across items, and ranges from 0 (maximal impairment) to 54 (maximally independent function).~This outcome is the change from baseline to week 12." (NCT03710642)
Timeframe: 12 weeks
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Treatment (Prazosin) | -1.47055 |
| Placebo Oral Capsule | -4.53993 |
"The ADCS-CGIC-A is the primary outcome measure. It will be anchored to disruptive agitation, the target behaviors in this study. It measures whether the effects of active treatment are substantial enough to be detected by a skilled and experienced clinician on the basis of a direct examination of the participant and an interview of the participant's primary caregiver and other LTC facility staff. The baseline assessment is qualitative therefore there is no score at baseline; post-baseline scores represent a change score compared to baseline.~The ADCS-CGIC-A is a 7-point scale that is structured as the clinician's assessment of change from baseline compared to the ADCS-CGIC-A Baseline Worksheet. There is no baseline score; post-baseline scores range from 1 (improvement) to 7 (worsening). A score of 1-2 indicates clinically meaningful improvement; a score of 3-5 indicates no clinically meaningful change; a score of 6-7 indicates clinically meaningful worsening." (NCT03710642)
Timeframe: From Baseline through Week 12.
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Treatment (Prazosin) | 3.434 |
| Placebo Oral Capsule | 3.442 |
"Comparison of effects on caregiver distress/occupational disruptiveness scores on the NPI/NPI-NH. Minimum score is 0 and maximum score is 60. A higher score is a worse outcome.~This outcome is the change from baseline to week 12." (NCT03710642)
Timeframe: 12 weeks
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Treatment (Prazosin) | -2.4438 |
| Placebo Oral Capsule | 0.9446 |
"The NPI was designed to characterize the neuropsychiatric symptoms and psychopathology of patients with AD and other dementias residing in the community about which information was obtained from family caregivers. The content of the questions and their scoring in the NPI-NH are identical to those of the NPI except for some slight rephrasing to be consistent with the LTC environment where information is gathered from professional caregivers. Assessment of the impact of behavioral disturbances on family and professional caregivers, is assessed by a caregiver distress scale in the NPI and an occupational disruptiveness scale in the NPI-NH; scoring of this component remains identical. Minimum score is 0 and highest score is 144. A higher score means a worse outcome.~This outcome is the change from baseline to week 12." (NCT03710642)
Timeframe: 12 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Treatment (Prazosin) | -6.033 |
| Placebo Oral Capsule | 5.506 |
Cumulative total dose of Lorazepam rescue medication administered during the trial. Information on the total mg rescue lorazepam administered will be collected as additional secondary outcome measures. If prazosin is more effective than placebo, it is predicted that participants randomized to prazosin will be prescribed lower cumulative mg of rescue lorazepam for management of persistent or worsening disruptive agitation. (NCT03710642)
Timeframe: 12 weeks
| Intervention | mg (Mean) |
|---|---|
| Treatment (Prazosin) | 0.25 |
| Placebo Oral Capsule | 0.14 |
Comparison of proportions of responders versus non responders on the ADCS-CGIC-A. Responders are defined as those with moderate or marked improvement in agitation symptoms compared to baseline assessment. (NCT03710642)
Timeframe: 12 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment (Prazosin) | 7 |
| Placebo Oral Capsule | 1 |
Cox proportional hazard modelling comparing the median time to drop out between treatment groups. (NCT03710642)
Timeframe: 12 weeks
| Intervention | days (Median) |
|---|---|
| Treatment (Prazosin) | 65.63 |
| Placebo Oral Capsule | 54.62 |
1 review available for dihydroxyphenylalanine and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Oxidative stress in Parkinson's disease and other neurodegenerative disorders.
Topics: Alzheimer Disease; Basal Ganglia Diseases; Cell Death; Dihydroxyphenylalanine; Dopamine Agents; Glut | 1996 |
1 trial available for dihydroxyphenylalanine and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Striatal Blood-Brain Barrier Opening in Parkinson's Disease Dementia: A Pilot Exploratory Study.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Blood-Brain Barrier; Corpus Striatum; Dementia; Dihydroxyp | 2022 |
12 other studies available for dihydroxyphenylalanine and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Dopamine neuronal loss contributes to memory and reward dysfunction in a model of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Apoptosis; Cell Death; Dendritic Spines; Dihydroxyphenylalanine; Disease | 2017 |
Structure-activity relationship of clovamide and its related compounds for the inhibition of amyloid β aggregation.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Cacao; Catechols; Cinnamates; Dihydroxyphenylalanine; Huma | 2018 |
Covariance statistics and network analysis of brain PET imaging studies.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Brain; Case-Control Studies; Cross-Sectional Studies; Di | 2019 |
Dopamine and L-dopa disaggregate amyloid fibrils: implications for Parkinson's and Alzheimer's disease.
Topics: alpha-Synuclein; Alzheimer Disease; Amyloid; Amyloid beta-Peptides; Animals; Brain; Chromatography, | 2004 |
Monoamine metabolites in human cerebrospinal fluid. HPLC/ED method.
Topics: 3,4-Dihydroxyphenylacetic Acid; Alzheimer Disease; Chromatography, High Pressure Liquid; Depression; | 1984 |
Assessment of dopamine metabolism in brain of patients with dementia by means of 18F-fluorodopa and PET.
Topics: Aged; Alzheimer Disease; Analysis of Variance; Brain; Corpus Striatum; Dementia; Dementia, Vascular; | 1994 |
Striatal dopamine metabolism correlated with frontotemporal glucose utilization in Alzheimer's disease: a double-tracer PET study.
Topics: Aged; Alzheimer Disease; Brain; Corpus Striatum; Dihydroxyphenylalanine; Dopamine; Female; Fluorodeo | 1997 |
Patterns of cerebrospinal fluid catechols support increased central noradrenergic responsiveness in aging and Alzheimer's disease.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Aged; Aging; Alzheimer Disease; Antimetabol | 1999 |
Positron emission tomography in degenerative disorders of the dopaminergic system.
Topics: Adult; Aged; Alzheimer Disease; Basal Ganglia; Brain; Brain Stem; Deoxyglucose; Dihydroxyphenylalani | 1992 |
Neuropathological features of Alzheimer's disease in non-demented parkinsonian patients.
Topics: Alzheimer Disease; Dihydroxyphenylalanine; Female; Humans; Male; Movement Disorders; Parkinson Disea | 1992 |
Analysis of monoamines in the cerebrospinal fluid of Chinese patients with Alzheimer's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Alzheimer Disease; China; Chromatography, High Pressure Liquid; Dihy | 1991 |
Simultaneous liquid-chromatographic determination of 3,4-dihydroxyphenylglycol, catecholamines, and 3,4-dihydroxyphenylalanine in plasma, and their responses to inhibition of monoamine oxidase.
Topics: Alzheimer Disease; Animals; Catecholamines; Chromatography, Liquid; Depression; Dihydroxyphenylalani | 1986 |